Press Releases Year None201920182017201620152014 November 11, 2019 Castle Biosciences Reports Third Quarter 2019 Results October 31, 2019 Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk October 29, 2019 Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting October 28, 2019 Castle Biosciences Presents Second Study Confirming Ability of DecisionDx-Melanoma to Inform Sentinel Lymph Node Biopsy Decisions at the 8th International Congress on Cancer Metastasis October 28, 2019 Castle Biosciences to Release Third Quarter 2019 Financial Results and Host Conference Call on Monday, November 11, 2019 October 18, 2019 Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node October 16, 2019 Castle Biosciences Announces Presentation of Prospective, Multicenter Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma October 7, 2019 Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma September 19, 2019 Castle Biosciences Added to Membership of US Small-Cap Russell 2000® Index September 3, 2019 Castle Biosciences Reports Second Quarter 2019 Results September 3, 2019 Castle Biosciences Announces Time Change for Presentation at the Baird 2019 Global Healthcare Conference August 27, 2019 Castle Biosciences to Present at the Baird 2019 Global Healthcare Conference August 22, 2019 Castle Biosciences to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, September 3, 2019 July 29, 2019 Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares July 24, 2019 Castle Biosciences Announces Pricing of Initial Public Offering July 11, 2019 Newly Published Study Establishes Evidence-Based Population for Clinical Use of DecisionDx-Melanoma in Patients with Thin Cutaneous Melanoma Tumors June 6, 2019 Analysis of Newly Expanded Cumulative Cohort Demonstrates that DecisionDx-Melanoma Improves Risk Prediction for Patients with Cutaneous Melanoma June 4, 2019 Prospective, Multicenter Study of DecisionDx-Melanoma Supports Accuracy and Performance in Prediction of Cutaneous Melanoma Outcomes May 7, 2019 Castle Biosciences’ Cutaneous Squamous Cell Carcinoma Prognostic Test Development Update Presented at the American College of Mohs Surgery Annual Meeting April 24, 2019 Castle Biosciences Receives 2019 Technology Innovation in Melanoma Award from American Skin Association April 18, 2019 American Cancer Society’s Newly Formed Philanthropic Impact Fund Makes First Investment April 11, 2019 Newly Published Independent, Prospective Study Reinforces Prognostic Accuracy of DecisionDx-Melanoma in Cutaneous Melanoma March 25, 2019 Castle Biosciences Announces Presentation of 5-Year Prospective, Multicenter Clinical Outcome Study Confirming Accuracy and Impact of Uveal Melanoma Test March 6, 2019 Publication of Independent Prospective, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction March 4, 2019 Meta-Analysis Showing DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk Presented during Late-Breaking Research Session at the 2019 AAD Annual Meeting February 7, 2019 Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck January 30, 2019 Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions January 7, 2019 Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study
Press Releases Year None201920182017201620152014 November 11, 2019 Castle Biosciences Reports Third Quarter 2019 Results October 31, 2019 Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk October 29, 2019 Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting October 28, 2019 Castle Biosciences Presents Second Study Confirming Ability of DecisionDx-Melanoma to Inform Sentinel Lymph Node Biopsy Decisions at the 8th International Congress on Cancer Metastasis October 28, 2019 Castle Biosciences to Release Third Quarter 2019 Financial Results and Host Conference Call on Monday, November 11, 2019 October 18, 2019 Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node October 16, 2019 Castle Biosciences Announces Presentation of Prospective, Multicenter Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma October 7, 2019 Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma September 19, 2019 Castle Biosciences Added to Membership of US Small-Cap Russell 2000® Index September 3, 2019 Castle Biosciences Reports Second Quarter 2019 Results September 3, 2019 Castle Biosciences Announces Time Change for Presentation at the Baird 2019 Global Healthcare Conference August 27, 2019 Castle Biosciences to Present at the Baird 2019 Global Healthcare Conference August 22, 2019 Castle Biosciences to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, September 3, 2019 July 29, 2019 Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares July 24, 2019 Castle Biosciences Announces Pricing of Initial Public Offering July 11, 2019 Newly Published Study Establishes Evidence-Based Population for Clinical Use of DecisionDx-Melanoma in Patients with Thin Cutaneous Melanoma Tumors June 6, 2019 Analysis of Newly Expanded Cumulative Cohort Demonstrates that DecisionDx-Melanoma Improves Risk Prediction for Patients with Cutaneous Melanoma June 4, 2019 Prospective, Multicenter Study of DecisionDx-Melanoma Supports Accuracy and Performance in Prediction of Cutaneous Melanoma Outcomes May 7, 2019 Castle Biosciences’ Cutaneous Squamous Cell Carcinoma Prognostic Test Development Update Presented at the American College of Mohs Surgery Annual Meeting April 24, 2019 Castle Biosciences Receives 2019 Technology Innovation in Melanoma Award from American Skin Association April 18, 2019 American Cancer Society’s Newly Formed Philanthropic Impact Fund Makes First Investment April 11, 2019 Newly Published Independent, Prospective Study Reinforces Prognostic Accuracy of DecisionDx-Melanoma in Cutaneous Melanoma March 25, 2019 Castle Biosciences Announces Presentation of 5-Year Prospective, Multicenter Clinical Outcome Study Confirming Accuracy and Impact of Uveal Melanoma Test March 6, 2019 Publication of Independent Prospective, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction March 4, 2019 Meta-Analysis Showing DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk Presented during Late-Breaking Research Session at the 2019 AAD Annual Meeting February 7, 2019 Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck January 30, 2019 Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions January 7, 2019 Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study
October 31, 2019 Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk
October 29, 2019 Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting
October 28, 2019 Castle Biosciences Presents Second Study Confirming Ability of DecisionDx-Melanoma to Inform Sentinel Lymph Node Biopsy Decisions at the 8th International Congress on Cancer Metastasis
October 28, 2019 Castle Biosciences to Release Third Quarter 2019 Financial Results and Host Conference Call on Monday, November 11, 2019
October 18, 2019 Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node
October 16, 2019 Castle Biosciences Announces Presentation of Prospective, Multicenter Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma
October 7, 2019 Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma
September 3, 2019 Castle Biosciences Announces Time Change for Presentation at the Baird 2019 Global Healthcare Conference
August 22, 2019 Castle Biosciences to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, September 3, 2019
July 29, 2019 Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 11, 2019 Newly Published Study Establishes Evidence-Based Population for Clinical Use of DecisionDx-Melanoma in Patients with Thin Cutaneous Melanoma Tumors
June 6, 2019 Analysis of Newly Expanded Cumulative Cohort Demonstrates that DecisionDx-Melanoma Improves Risk Prediction for Patients with Cutaneous Melanoma
June 4, 2019 Prospective, Multicenter Study of DecisionDx-Melanoma Supports Accuracy and Performance in Prediction of Cutaneous Melanoma Outcomes
May 7, 2019 Castle Biosciences’ Cutaneous Squamous Cell Carcinoma Prognostic Test Development Update Presented at the American College of Mohs Surgery Annual Meeting
April 24, 2019 Castle Biosciences Receives 2019 Technology Innovation in Melanoma Award from American Skin Association
April 18, 2019 American Cancer Society’s Newly Formed Philanthropic Impact Fund Makes First Investment
April 11, 2019 Newly Published Independent, Prospective Study Reinforces Prognostic Accuracy of DecisionDx-Melanoma in Cutaneous Melanoma
March 25, 2019 Castle Biosciences Announces Presentation of 5-Year Prospective, Multicenter Clinical Outcome Study Confirming Accuracy and Impact of Uveal Melanoma Test
March 6, 2019 Publication of Independent Prospective, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction
March 4, 2019 Meta-Analysis Showing DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk Presented during Late-Breaking Research Session at the 2019 AAD Annual Meeting
February 7, 2019 Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck
January 30, 2019 Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions
January 7, 2019 Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study
